AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00953173 — intervention group
Intervention type: DEVICE
Intervention: LAP-BAND AP® Adjustable Gastric Banding System
Description: The LAP-BAND AP® is a device surgically implanted via a laparoscopic procedure. It is designed to induce weight loss in severely obese patients by limiting food consumption.
Study NCT04156802 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real TBS to the mPFC
Description: This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded)
Study NCT04156802 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TBS to the mPFC
Description: This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the coil.
Study NCT04156802 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real TBS to the MC
Description: This will be delivered with the Magventure Magpro system (double blinded).
Study NCT04156802 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TBS to the MC
Description: This will be delivered with the Magventure Magpro system (double blinded). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the coil.
Study NCT02737410 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gut-directed Hypnotherapy
Description: The GHT protocol used was the Manchester protocol of GHT and consisted of 10 weekly sessions (45 min), with six patients per group over a treatment period of 12 weeks. GHT was performed at the University Hospital by two experienced physicians trained in Manchester (UK).
Study NCT03644966 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium infantis
Description: Probiotics
Study NCT03644966 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic probiotic tablet
Study NCT03644966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: Per Infectious Disease Society guidelines for Antimicrobial treatment of uncomplicated cystitis and pyelonephritis in women
Study NCT03644966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: Per Infectious Disease Society guidelines for Antimicrobial treatment of uncomplicated cystitis and pyelonephritis in women
Study NCT02822118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chang'an I Recipe
Description: Patients in this group were administered the Chang'an I Recipe, 150ml/bag, 3 times/day for 8 weeks.
Study NCT02822118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in this group were administered the placebo, 150ml/bag, times/day for 8 weeks.
Study NCT02784730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Iterative PICC placement
Description: Intervention is the catheterisation strategy (not the device)
Study NCT02784730 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long term PAC placement
Description: Intervention is the catheterisation strategy (not the device)
Study NCT03744208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-EGFR monoclonal antibody
Description: DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression
Study NCT00499005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntommetrine and Carbetocin
Description: Syntommetrine 1ml and Carbetocin 100microgram
Study NCT00499005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntommetrine and Carbetocin
Description: Syntommetrine 1ml and Carbetocin 100micgrams
Study NCT04089449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRT811
Description: PRT811 will be administered orally
Study NCT01002924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC145
Description: EC145 will be administered intravenously at a dose of 2.5 mg. Dosing will occur on Monday, Wednesday, and Friday of weeks 1 and 3 of each 4-week cycle. No therapy will be administered during weeks 2 and 4.
Study NCT04600947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP002
Description: 10 mg/kg administered as IV infusion on Day 1 of each 14-day cycle.
Study NCT00036634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide
Description: Tenofovir alafenamide tablet(s) administered orally once daily
Study NCT03636789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurological consultation
Description: study of horizontal, vertical, reflex and voluntary saccades, and of horizontal and vertical ocular pursuit by a BrainTracker eye-oculography system
Study NCT01200368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (13vPnC)
Description: 0.5 mL per dose, 4 doses
Study NCT01200368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: diphtheria, tetanus, and acellular pertussis vaccine (DTaP)
Description: 0.5 mL per dose, 4 doses
Study NCT01200368 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7-valent pneumococcal conjugate vaccine (7vPnC)
Description: 0.5 mL per dose, 4 doses
Study NCT01200368 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP
Description: 0.5 mL per dose, 4 doses
Study NCT06342518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Description: The ESWT group received radial ESWT each session with a total of 2000 pulses at a frequency of 10 Hz. A gel was used at the interface, and the air pressure was set at 1.8 bar per session.
Study NCT06342518 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham ESWT
Description: The Sham-ESWT group received Sham radial ESWT each session, but without actual contact of the applicator. To enhance the illusion of treatment, gel was applied, and the device emitted sound at every shock
Study NCT06342518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resting Splint , Exercises and ice
Description: Ensuring proper usage of the wrist resting splint by the patient was confirmed during follow-up visits. The physician instructed the patients on stretching and strengthening exercises for wrist extensors, which they were asked to perform three times a day. Application of ice for 20 minutes every 3-4 hours during painful periods was recommended. During follow-up visits patients confirmed that they adherence to exercises and recommendations.
Study NCT06342518 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Resting Splint , Exercises and ice
Description: Ensuring proper usage of the wrist resting splint by the patient was confirmed during follow-up visits. The physician instructed the patients on stretching and strengthening exercises for wrist extensors, which they were asked to perform three times a day. Application of ice for 20 minutes every 3-4 hours during painful periods was recommended. During follow-up visits patients confirmed that they adherence to exercises and recommendations.
Study NCT00992355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin 0.3% - Dexamethasone 0.1%
Study NCT00992355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin 0.3% - Dexamethasone 0.1% plus Ketorolac tromethamine 0.5%
Study NCT02968368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric maltol
Study NCT02968368 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03349788 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LCA-nP
Description: The group underwent lapaoroscopic radical rectectomy without preserving left colic artery.
Study NCT03349788 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LCA-P
Description: The group underwent lapaoroscopic radical rectectomy with preserving left colic artery.
Study NCT02167516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glucosamine sulfate
Description: glucosamine sulfate capsule: One each time, 3 times a day, Oral,for 4 weeks placebo(for Xinfeng capsule): Three each time, 3 times a day, Oral,for 4 weeks
Study NCT02167516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xinfeng capsule
Description: Xinfeng capsule:Three each time, 3 times a day, Oral,for 4 weeks placebo(for glucosamine sulfate capsule): One each time, 3 times a day, Oral,for 4 weeks
Study NCT03654937 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Vaccination
Description: Influenza vaccination Influsplit Tetra 2016/2017, GlaxoSmithKline GmbH \& Co. KG, Munich, Germany, batch: AFLBA 152AB.
Study NCT01460758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medial Frontal rTMS Double-Cone-Coil
Description: High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodmann area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold.
Study NCT01460758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left DLPFC Butterfly Coil
Description: High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 10 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold.
Study NCT01460758 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo Stimulation
Description: Sham Stimulation (conventional butterfly-coil, angled 45°): left DLPFC continuous rTMS, 10 Hz, 2000 Stimuli each session, 110% motor threshold
Study NCT02258646 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training at home
Study NCT02258646 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemonitoring and education/self-management
Study NCT00694668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral treatment
Description: Brief cognitive behavioral therapy (12 sessions)
Study NCT00694668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based cognitive therapy
Description: 9 sessions MBCT in a group-format (up to 8 persons)
Study NCT01210898 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted seasonal influenza vaccine
Description: Full or half dose of adjuvanted seasonal influenza vaccine; Full or half dose of unadjuvanted seasonal influenza vaccine
Study NCT00747968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Byetta, Exenatide
Description: Drug: Exenatide or placebo Dosage form: Infusion Dosage: Exenatide (Eli Lilly/Amylin Pharmaceuticals) 0.066 pmol\*kg-1\*min-1 Duration: 5 hours Frequency: Drug given once, placebo given once
Study NCT00747968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Byetta, Exenatide
Description: Drug: Exenatide or placebo Dosage form: Infusion Dosage: Exenatide (Eli Lilly/Amylin Pharmaceuticals) 0.066 pmol\*kg-1\*min-1 Duration: 5 hours Frequency: Drug given once, placebo given once
Study NCT04123496 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
Study NCT03189030 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pLADD
Description: via IV infusion
Study NCT03440671 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hutox Inj
Description: Hutox Inj(Clostridium botulinum type A)
Study NCT03440671 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botox Inj
Description: Botox Inj(Clostridium botulinum type A)
Study NCT00945984 — intervention group
Intervention type: PROCEDURE
Intervention: Radical nephrectomy
Description: Surgical options to treat localized renal cell carcinoma
Study NCT04321304 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: Uses weak electrical current (2 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo-like effects or participant expectation bias.
Study NCT04321304 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation at 2 mA
Description: Uses weak electrical current (2 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
Study NCT04321304 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation at 4 mA
Description: Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
Study NCT03554291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine 20 MG
Description: Famotidine 20 mg capsule taken daily for 24 weeks.
Study NCT03554291 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule taken daily for 24 weeks.
Study NCT02460770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells
Description: After bone-marrow aspiration by an authorized person, mesenchymal stem cells were isolated and cultured during 17 days by the French Blood Establishment. Then, patients receive intramyocardial injections of mesenchymal stem cells during device surgery.
Study NCT00648219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan Medoxomil Tablets 40 mg
Description: 40mg, single dose fed
Study NCT00648219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benicar® Tablets 40 mg
Description: 40mg, single dose fed
Study NCT02627599 — intervention group
Intervention type: DEVICE
Intervention: Breath Responsive Variable Bolus Oxygen Conserving Device
Description: Mini Electronic Oxygen Conserving Device
Study NCT04110483 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thulium fiber laser en-bloc resection of non-muscle-invasive bladder cancer
Description: After cystoscopy and determining tumor topography, a circumferential incision around the tumor is made in the visually intact bladder mucosa (approximately 10 mm from the edges of the tumor). It allows for accurate morphological evaluation of the surgical margin. After that, the incision is continued deeper into the muscular layer. Having identified the layer, the surgeon resects the base of the tumor with the muscular layer using traction and incisions of the muscle fibers. Making incisions in the muscular layer requires precision, a full bladder and adequate guidance with visualization techniques. Traction may be employed with the help of the tip of the resectoscope or working element. After complete tumor resection, local hemostasis was performed.
Study NCT04110483 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral resection of non-muscle-invasive bladder cancer
Description: After cystoscopy and determining tumor topography, a step-by-step resection of a tumor is done. Firstly, visible tumor is resected, then resection continues to the apparently normal mucosa on the border of the tumor, than resection of the muscle layer at the base of the tumor is performed until normal muscle fibers are visible.
Study NCT00480779 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: GLB Group
Description: The Group Lifestyle Balance (GLB) program is a lifestyle change program adapted from the successful lifestyle intervention utilized in the Diabetes Prevention Program. For this arm, the intervention is delivered in face-to-face groups by a trained lifestyle coach.
Study NCT00480779 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: GLB DVD
Description: The Group Lifestyle Balance (GLB) program is a lifestyle change program adapted from the successful lifestyle intervention utilized in the Diabetes Prevention Program. For this arm, the intervention is delivered via DVD and weekly telephone contact with a trained lifestyle coach.
Study NCT04043312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magstim SuperRapid
Description: Transcutaneous magnetic stimulation targeting the left stellate ganglion.
Study NCT04043312 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Magstim SuperRapid
Description: Sham transcutaneous magnetic stimulation.
Study NCT00876304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04802540
Description: Multiple ascending doses for 10 days; planned doses include capsules totaling 5 mg and 20 mg every 12 hours, with additional doses determined based on accumulating data
Study NCT00876304 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules every 12 hours for 10 days
Study NCT02445027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MGH OCT Imaging Capsule
Description: Imaging of the esophagus using the OCT Capsule and system.
Study NCT01172652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: The minimum dose during study participation will be 40 mg/day, and the maximum dose allowed will be 160 mg/day.
Study NCT01172652 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive control
Study NCT00005669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin HCL
Description: Medication studied for ability to alter body weight and body composition.
Study NCT00005669 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control capsules for metformin
Study NCT00613509 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC(2) Melanoma multi-antigen therapeutic vaccine
Description: 0.5 mL, 2 cycles
Study NCT00613509 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intron A, Interferon alpha -2b
Description: 0.5 mL, 5 times per week for 4 weeks
Study NCT02166983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computer-assisted cognitive training
Description: Complete Lumosity cognitive exercises
Study NCT02166983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive intervention
Description: Complete Active Journaling cognitive exercises
Study NCT02166983 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mind-body intervention procedure
Description: Complete relaxation exercises
Study NCT02166983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: memory intervention
Description: Complete compensatory strategies
Study NCT02166983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT00560690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg oral three times a day for 6 months
Study NCT00560690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon
Description: 180 micrograms, or 1.5 micrograms/kg body weight weekly SQ injection for 6 or 12 months depending on genotype
Study NCT04135872 — intervention group
Intervention type: OTHER
Intervention: strengthened nuitritional treatment
Description: improving nutritional status by nasal feeding for dysphagia or iv. albumin when serum albumin level lower than 35g/L
Study NCT04167150 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: tart cherry juice concentrate is a commercial product provided by King Orchards (Central Lake, MI)
Description: Participants were instructed to reconstitute the tart cherry juice concentrate in 8 fl oz of water and consume either 1x or 2x daily for 3 months.
Study NCT04167150 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: tart cherry juice concentrate is a commercial product provided by King Orchards (Central Lake, MI)
Description: Participants were instructed to reconstitute the tart cherry juice concentrate in 8 fl oz of water and consume either 1x or 2x daily for 3 months.
Study NCT02400658 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IORT with CT-Guided HDR Brachytherapy
Description: This therapy targets the cancer cells directly, reducing the volume of breast tissue exposed to the radiation and the risks involved with the radiation. CT imaging will be used via a multichannel/multi-dwell balloon catheter to better sculpt the cancer away from the heart, skin, and ribs.
Study NCT04459936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: URICORI
Description: Treatment for cardiovascular risk factors according to national guideline administered at the department of Rheumatology
Study NCT04459936 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL
Description: Treatment for cardiovascular risk factors according to national guideline administered at the General Practitioner
Study NCT04069650 — intervention group
Intervention type: PROCEDURE
Intervention: Free flap
Description: Free flap reconstruction of the oral cavity
Study NCT00560690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pegylated interferon
Description: 180 micrograms, or 1.5 micrograms/kg body weight weekly SQ injection for 6 or 12 months depending on genotype
Study NCT00560690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 800-1200 mg PO given in 2 divided doses for 6 to 12 months depending on weight and genotype